Industry Newsclinical trialsimmunologyhematologypharma partnerships
Protagonist Therapeutics Raises Price Target, Advances Pipeline
4.8
On Jan. 30 H.C. Wainwright raised its price target on Protagonist Therapeutics (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating, the firm said. In early February a company director sold 20,000 shares for about $1.7 million as Protagonist reported two potential late-stage assets — icotrokinra and rusfertide — with NDAs submitted in 2025 and multiple Phase 2/3 readouts expected, supported by J&J and Takeda partnerships.
Key Points
- 1Reports H.C. Wainwright raised PTGX price target to $117 and reiterated a Buy on Jan 30.
- 2Highlights late-stage momentum with NDAs submitted in 2025 for Icotrokinra and Rusfertide.
- 3Suggests partnerships with J&J and Takeda provide milestone royalties, aiding non-dilutive funding and risk management.
Scoring Rationale
Moderate company-specific developments with official signals, limited by niche scope and promotional, shallow coverage lacking broader industry impact.
Sources
Public references used for this report.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
Used by DS/ML engineers at top companies
250 free problems · No credit card
See all Health & Insurance problems